

OCT 1 1 2002

510(k) Summary

SUBMITTER:

Stöckert Instrumente GmbH

Lindberghstrasse 25

D-80939 Munich, Germany

CONTACT PERSON:

Mr. Helmut Höfl

Director, Quality and Regulatory Affairs

Phone: 49-89-323-010 Fax: 49-89-323-01100

DATE PREPARED:

May 10, 2002

DEVICE TRADE NAME: Stöckert Coronary Perfusion Cannulae

COMMON/USUAL NAME:

Antegrade Cardioplegia Cannulae

CLASSIFICATION NAME:

Cardiopulmonary Bypass Vascular Catheter, Cannula or Tubing

PREDICATE DEVICE:

Medtronic DLP Coronary Ostial Perfusion Cannulae

DEVICE DESCRIPTION:

The Stöckert Coronary Perfusion Cannulae are comprised of either a flexible plastic (PVC) or a malleable stainless steel body, with a soft silicone tip and either a ¼" barbed tubing connector or a luer lock. They are offered in various tip outer diameters ranging from 3.0 to 5.0 mm (9 to 15 Fr). The P605, P607, P615, and P617 Series Stöckert Coronary Perfusion Cannulae are 26 cm long. The P606, P608, P616, and P618 Series Stöckert Coronary Perfusion Cannulae are 14 cm long.

INDICATIONS FOR USE

The Stöckert Coronary Perfusion Cannulae are intended to be used to cannulate the coronary ostium and to deliver cardioplegic solution during cardiopulmonary surgery for periods of up to six hours.

STATEMENT OF TECHNICAL CHARACTERISTICS COMPARISON

In-vitro performance and biocompatibility tests demonstrate substantial equivalency of the Stöckert Coronary Perfusion Cannulae to the Medtronic DLP Coronary Ostial Perfusion Cannulae. The devices share the same intended use, design features, and performance characteristics.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

OCT 1 1 2002

Stöckert Instrumente GmbH c/o Ms. Lynne Leonard Leonard Regulatory Consulting 20193 Goins Drive Morrison, CO 80465

Re: K022280

Stöckert Coronary Perfusion Cannulae

Regulation Number: 870.4210

Regulation Name: Cardiopulmonary Bypass Vascular Catheter, Cannula, and Tubing

Regulatory Class: Class II (two)

Product Code: DWF Dated: July 11, 2002 Received: July 15, 2002

Dear Ms. Leonard:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Page 2 – Ms. Lynne Leonard

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4646. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html

Sincerely yours,

Bram D. Zuckerman, M.D.

-Director

Division of Cardiovascular Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

Enclosure

ı	ndia	ati	one	For	Use
ı	11 1 () 1 (<i>-</i> 21111	UH 15	гог	USE

Prescription Use

(Per 21 CFR 801.109)

Device Name:

Stöckert Coronary Perfusion Cannulae

Indications For Use:

The Stöckert Coronary Perfusion Cannulae are intended to be used to cannulate the coronary ostium and to deliver cardioplegic solution during cardiopulmonary surgery for periods of up to six hours.

PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

OR

Over-The-Counter Use __

Division of Cardiovas 510(k) Number____